Shanghai Bio-heart Biological Technology Co., Ltd.

SEHK:2185 株式レポート

時価総額：HK$433.3m

Shanghai Bio-heart Biological Technology マネジメント

マネジメント 基準チェック /24

現在、CEO に関する十分な情報がありません。

主要情報

Philip Wang

最高経営責任者

CN¥30.5m

報酬総額

CEO給与比率2.3%
CEO在任期間9.9yrs
CEOの所有権18.8%
経営陣の平均在職期間3.8yrs
取締役会の平均在任期間2yrs

経営陣の近況

Recent updates

We Think Shanghai Bio-heart Biological Technology (HKG:2185) Can Afford To Drive Business Growth

Nov 15
We Think Shanghai Bio-heart Biological Technology (HKG:2185) Can Afford To Drive Business Growth

Shanghai Bio-heart Biological Technology (HKG:2185) Is In A Good Position To Deliver On Growth Plans

Jul 24
Shanghai Bio-heart Biological Technology (HKG:2185) Is In A Good Position To Deliver On Growth Plans

Companies Like Shanghai Bio-heart Biological Technology (HKG:2185) Are In A Position To Invest In Growth

Feb 22
Companies Like Shanghai Bio-heart Biological Technology (HKG:2185) Are In A Position To Invest In Growth

Companies Like Shanghai Bio-heart Biological Technology (HKG:2185) Are In A Position To Invest In Growth

Nov 03
Companies Like Shanghai Bio-heart Biological Technology (HKG:2185) Are In A Position To Invest In Growth

We Think Shanghai Bio-heart Biological Technology (HKG:2185) Can Afford To Drive Business Growth

May 12
We Think Shanghai Bio-heart Biological Technology (HKG:2185) Can Afford To Drive Business Growth

We're Not Worried About Shanghai Bio-heart Biological Technology's (HKG:2185) Cash Burn

Sep 19
We're Not Worried About Shanghai Bio-heart Biological Technology's (HKG:2185) Cash Burn

Shanghai Bio-heart Biological Technology (HKG:2185) Is In A Good Position To Deliver On Growth Plans

Jun 03
Shanghai Bio-heart Biological Technology (HKG:2185) Is In A Good Position To Deliver On Growth Plans

CEO報酬分析

Shanghai Bio-heart Biological Technology の収益と比較して、Philip Wang の報酬はどのように変化したか？
日付総報酬給与会社業績
Jun 30 2024n/an/a

-CN¥116m

Mar 31 2024n/an/a

-CN¥146m

Dec 31 2023CN¥30mCN¥708k

-CN¥176m

Sep 30 2023n/an/a

-CN¥182m

Jun 30 2023n/an/a

-CN¥189m

Mar 31 2023n/an/a

-CN¥197m

Dec 31 2022CN¥86mCN¥708k

-CN¥204m

Sep 30 2022n/an/a

-CN¥234m

Jun 30 2022n/an/a

-CN¥263m

Mar 31 2022n/an/a

-CN¥312m

Dec 31 2021CN¥192mCN¥709k

-CN¥361m

Sep 30 2021n/an/a

-CN¥437m

Jun 30 2021n/an/a

-CN¥512m

Mar 31 2021n/an/a

-CN¥419m

Dec 31 2020CN¥61mCN¥491k

-CN¥326m

Dec 31 2019CN¥418kCN¥418k

-CN¥24m

報酬と市場: Philipの 総報酬 ($USD 4.21M ) は、 Hong Kong市場 ($USD 233.03K ) の同規模の企業の平均を上回っています。

報酬と収益: Philipの報酬は、過去 1 年間の会社の業績と一致しています。

CEO（最高経営責任者

Philip Wang (56 yo)

9.9yrs

在職期間

CN¥30,469,000

報酬

Mr. Li Wang, also known as Philip, serves as Executive Chairman of the Board and Chief Executive Officer at Shanghai Bio-heart Biological Technology Co., Ltd. and serves as its General Manager since July 1...

リーダーシップ・チーム

名称ポジション在職期間報酬所有権
Li Wang
Executive Chairman of the Boardno dataCN¥30.47m18.75%
HK$ 81.2m
Yunqing Wang
CFO, Joint Company Secretary & Executive Director4yrsCN¥5.21mデータなし
Peili Wang
Financial Manager & Executive Director1.8yrsCN¥2.37mデータなし
Bradley Hubbard
Chief Medical Officer3.7yrsデータなしデータなし
Siu Ying Kwok
Joint Company Secretary3.9yrsデータなしデータなし
Tao Cai
Chairperson of the Board of Supervisors & Head of Technology of BRSno dataCN¥4.73mデータなし

3.8yrs

平均在職期間

40yo

平均年齢

経験豊富な経営陣: 2185の経営陣は 経験豊富 であると考えられます ( 3.8年の平均在職年数)。

取締役

名称ポジション在職期間報酬所有権
Li Wang
Executive Chairman of the Board9.9yrsCN¥30.47m18.75%
HK$ 81.2m
Yunqing Wang
CFO, Joint Company Secretary & Executive Director4.2yrsCN¥5.21mデータなし
Peili Wang
Financial Manager & Executive Director2yrsCN¥2.37mデータなし
Tao Cai
Chairperson of the Board of Supervisors & Head of Technology of BRS3.9yrsCN¥4.73mデータなし
Xubo Lu
Independent Non-Executive Director4yrsCN¥400.00kデータなし
Yiqing Chen
Independent Non-Executive Directorless than a yearデータなしデータなし
Lei Zhu
Supervisor2yrsデータなしデータなし
Junyi Wang
Employee Representative Supervisor1.3yrsデータなしデータなし
Yifei Jiang
Independent Non-Executive Directorless than a yearデータなしデータなし

2.0yrs

平均在職期間

39.5yo

平均年齢

経験豊富なボード: 2185の 取締役会 は 経験豊富 ではない ( 2年の平均在任期間) ため、新しい取締役会が必要であると考えられます。